Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Remibrutinib in Hepatic Impairment
NCT05753592Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of remibrutinib in chronic spontaneous urticaria (CSU) and multiple sclerosis (MS) (2 arms), sponsored by Novartis. Primary endpoints: Maximum Steady-State Plasma Concentration at 72 hours, Area Under the Plasma Concentration-Time Curve Over the Dosing Interval at 72 hours and 3 more. Started Oct 2022; status: completed.
02
Drugs
remibrutinib
03
Conditions
chronic spontaneous urticaria (CSU)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05753592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753592.